Developing peptide and oligonucleotide APIs demands a precise balance of efficiency, quality and compliance. To meet the growing demand for high-quality APIs for both clinical and commercial purposes, Bachem has established a comprehensive CMC development concept. This approach is tailored to each product, ensuring flexibility while maintaining rigorous standards. The concept involves a thorough analysis of process-related risks and ensures full alignment with both clinical timelines and regulatory guidelines.
Don’t miss out as we share valuable insights into optimising CMC product development, characterisation, and risk management, all designed to deliver high-quality materials that meet the toughest clinical and regulatory requirements.
Key Challenges that we address:
- High-quality API production: How Bachem ensures the development of top-tier peptide and oligonucleotide APIs.
- Risk mitigation strategies: Managing and reducing process-related risks to enhance product stability and compliance.
- Meeting regulatory and clinical timelines: Aligning process development with evolving industry guidelines and approval pathways.
- Comprehensive CMC development concept: A flexible approach tailored to the unique needs of each product.
Key benefits/takeaways from the webinar:
- In-depth risk analysis: Learn how we assess and address potential risks in CMC manufacturing control.
